- Home
- CGTL vs CKPT Comparison
CGTL vs CKPT Comparison
Compare CGTL & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTL
- CKPT
- Stock Information
- Founded
- CGTL 2016
- CKPT 2014
- Country
- CGTL Hong Kong
- CKPT United States
- Employees
- CGTL N/A
- CKPT N/A
- Industry
- CGTL
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- CGTL
- CKPT Health Care
- Exchange
- CGTL NYSE
- CKPT Nasdaq
- Market Cap
- CGTL 152.2M
- CKPT 151.9M
- IPO Year
- CGTL 2024
- CKPT 2017
- Fundamental
- Price
- CGTL $5.30
- CKPT $3.18
- Analyst Decision
- CGTL
- CKPT Strong Buy
- Analyst Count
- CGTL 0
- CKPT 2
- Target Price
- CGTL N/A
- CKPT $13.50
- AVG Volume (30 Days)
- CGTL 71.8K
- CKPT 1.3M
- Earning Date
- CGTL 02-15-2025
- CKPT 11-12-2024
- Dividend Yield
- CGTL N/A
- CKPT N/A
- EPS Growth
- CGTL N/A
- CKPT N/A
- EPS
- CGTL 0.14
- CKPT N/A
- Revenue
- CGTL $42,953,944.00
- CKPT $47,000.00
- Revenue This Year
- CGTL N/A
- CKPT N/A
- Revenue Next Year
- CGTL N/A
- CKPT $172,016.02
- P/E Ratio
- CGTL $38.38
- CKPT N/A
- Revenue Growth
- CGTL N/A
- CKPT N/A
- 52 Week Low
- CGTL $3.37
- CKPT $1.38
- 52 Week High
- CGTL $10.59
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- CGTL N/A
- CKPT 42.32
- Support Level
- CGTL N/A
- CKPT $3.07
- Resistance Level
- CGTL N/A
- CKPT $3.42
- Average True Range (ATR)
- CGTL 0.00
- CKPT 0.21
- MACD
- CGTL 0.00
- CKPT -0.02
- Stochastic Oscillator
- CGTL 0.00
- CKPT 15.71
About CGTL CREATIVE GLOBAL TECHNOLOGY HOLDINGS LIMITED
Creative Global Technology Holdings Ltd Conducts its business through its subsidiary, which is a Hong Kong-based company sourcing and reselling recycled consumer electronic devices, currently mostly smartphones, tablets, and laptops.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.